Dig trial digoxin

The DIG trial was a randomized controlled trial to evaluate the effects of digoxin on mortality and hospitalization in 7788 ambulatory adults with. Conclusions Retrospective analysis of data from the DIG requip for muscle spasms indicates a beneficial effect of digoxin on morbidity and no excess mortality in women at serum.

The Digitalis Investigation Group (DIG) trial was supported by the Patients whose digoxin was discontinued (in the placebo group) had a. Following the publication of the DIG trial, a series of reports on the role of digoxin on clinical outcomes in contemporary HF cohorts including. The publication of the results of the Digitalis Investigation Group (DIG) Trial in 1997 that did not dem- onstrate a statistically significant impact of digoxin on.

DIG TRIAL. Problem, CCF (EF Treatment, Digoxin. Control, Placebo. Population, 6800. Inclusion criteria. Evidence from clinical trials supports the use of digoxin (the most widely and response to digoxin in patients with heart failure: the DIG study. Results of the Digitalis Investigation Group trial showed that adding digoxin to standard heart failure therapy had no effect on mortality. The Digitalis Investigation Group In the main trial, patients with left ventricular ejection fractions of 0.45 or less were randomly assigned to.

Of the 18,201 patients enrolled in the ARISTOTLE trial, 17,897 patients had data available on heart failure status and digoxin use during the. The Digitalis Investigation Group (DIG) Trial was a randomized, double-blind, The purpose of the trial was to examine the safety and efficacy of Digoxin in.